Poor Responses to a Test Dose of Subcutaneous Octreotide Predict the Need for Adjuvant Therapy to Achieve 'Safe' Growth Hormone Levels

@article{Lindsay2004PoorRT,
  title={Poor Responses to a Test Dose of Subcutaneous Octreotide Predict the Need for Adjuvant Therapy to Achieve 'Safe' Growth Hormone Levels},
  author={John R. Lindsay and Erin M McConnell and Scott J Hunter and David R. McCance and Brian Sheridan and A. Brew Atkinson},
  journal={Pituitary},
  year={2004},
  volume={7},
  pages={139-144}
}
Objective: Somatostatin analogues are an established treatment in acromegaly. This study was designed to evaluate whether the acute serum growth hormone (GH) response to a test dose of octreotide in acromegaly predicts longer-term response to the drug at 3 years. Design and methods: In 23 patients, GH responses across 8 h to a subcutaneous test dose (50 μg) of octreotide were compared with GH levels after 3 years of therapy. The majority had pituitary surgery as primary therapy and at 3 years… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Similar Papers

Loading similar papers…